MeiraGTx Holdings plc filings document a clinical-stage genetic medicines company with ordinary shares listed on Nasdaq under MGTX. The company’s 8-K reports cover material definitive agreements, collaboration and license arrangements, asset purchases for genetic-medicine programs, Regulation FD clinical disclosures, operating and financial results, and amendments to note and warrant financing arrangements.
Its proxy materials describe shareholder voting matters, board governance, executive compensation, equity awards, and related corporate-governance disclosures. The filing record also documents capital structure, subsidiary guarantor arrangements, risk-oriented clinical and regulatory disclosures, and program-specific matters involving AAV-hAQP1, AAV-AIPL1, RPGR-related X-linked retinitis pigmentosa assets, and riboswitch technology.
Form 144 filing overview for MeiraGTx Holdings plc (MGTX)
The notice discloses a proposed sale of 47,500 ordinary shares through Merrill Lynch, 200 Park Avenue, New York, NY 10166. The transaction is scheduled for approximately 08 July 2025 on the NASDAQ exchange.
- Aggregate market value: $378,575
- Total shares outstanding: 80,365,359
- Percentage of float affected: ≈0.06%
The shares were originally acquired via incentive compensation stock grants on 02 March 2018 (35,625 shares) and 07 June 2018 (11,875 shares). The filer reports no other share sales within the past three months.
Because the sale represents a small fraction of outstanding stock and stems from equity compensation, the filing is generally considered routine. Investors often monitor Form 144s to gauge insider sentiment; however, the scale here is unlikely to materially impact market dynamics.
SEC Form 4 for MeiraGTx Holdings plc (MGTX) discloses that Richard Giroux, the company’s Chief Financial & Operating Officer, gifted 5,000 ordinary shares on 06/30/2025 (transaction code G, price $0). After this transaction, Giroux still owns 877,494 shares directly and 90,152 shares indirectly (5,152 via spouse; 85,000 via Aigle Healthcare Partners III LLC). No derivative positions were added or reduced, and the filing was signed on 07/02/2025. The Rule 10b5-1 checkbox is not marked, indicating the gift was not executed under a preset trading plan. The transaction reduces Giroux’s direct stake by approximately 0.6%, leaving his overall ownership essentially unchanged. There is no indication of operational or financial impact on MeiraGTx arising from this personal transfer.
MeiraGTx (NASDAQ:MGTX) filed an 8-K Regulation FD disclosure announcing it has obtained all required UK foreign-direct-investment clearances for its previously announced transactions with Hologen Ltd., signed March 9 2025.
The clearance removes the final regulatory hurdle, allowing the deal—which management expects to close in July 2025—to proceed to funding and execution.